Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to…
Month: January 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options If you purchased or acquired securities investing Kyverna common stock pursuant and/or traceable to the Offering…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Customers Bancorp To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Customers Bancorp between March 1, 2024 and August 8, 2024 and…
First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management SILVER SPRING, Md., Jan. 30, 2025 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marqeta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marqeta between May 7, 2024 and November 4, 2024 and would like to discuss…
